rewirebio.iobenchmarks
Benchmark

Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification study

Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.

2 evaluations · 4 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

2 recorded evaluations, 4 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

2 evaluations · 4 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: ACMG/AMP classification system with SVI recommendations (t2)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
24 Count (reclassified: VUS to likely benign)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..."
Configuration: ACMG/AMP classification system with SVI recommendations (t2)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
20% Proportion (reclassified: VUS to likely benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..."
Configuration: ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 (t3)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
101 Count (reclassified: VUS to benign or likely benign)
count · unknown

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t3 (ENIGMA VCEP) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)": "...83.5% (n = 101) of VUS were reclassified as B (n = 9) or LB (n = 92) (Figure 2A; t3)."
Configuration: ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 (t3)Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3)
Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
83.5% Proportion (reclassified: VUS to benign or likely benign)
percent · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Benet-Pages t3 (ENIGMA VCEP) reclassification of the 121-variant VUS cohort

Not reported

Aggregation: Not reported

Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)": "...83.5% (n = 101) of VUS were reclassified as B (n = 9) or LB (n = 92) (Figure 2A; t3)."

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Evaluation design

Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.

These source-backed links do not make different protocols or scores interchangeable.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 4 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

Baseline status by linked protocol

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run this benchmark

Choose a concrete protocol before running an evaluation. Its inputs, split and scoring rules determine which results can be compared.

Run instructions

No runnable recipe has been reviewed for this benchmark. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID uc-clinical-20261005-benet-pages-benchmark.

Source locator: Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)"; Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)"

Related records

Suggest a correction